



# KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

---

June 30<sup>th</sup> June , 2020

To,  
The Deputy Gen. Manager,  
Dept.of Corporate Services,  
BSE Ltd,  
P.J. Tower, Dalal Street,

**Sub: Outcome of the Board Meeting- audited financial results for 4th Quarter and financial year ended 31st March, 2020**

**Ref: Scrip Code - 542322**

Dear Sir/Madam,

We hereby inform you that, the Meeting of Board of Directors of the Company was held Today viz., Tuesday, 30<sup>th</sup> of June, 2020 at registered office at 12:30 PM and concluded at 5:59 PM

The outcome of the Board meeting, *inter alia*, is as under:

**Approval of the Audited Financial Results for the 4<sup>th</sup> quarter and financial year ended 31<sup>st</sup> March, 2020**

The Board considered and approved the unaudited results for the 4<sup>th</sup> quarter and financial year ended 31<sup>st</sup> March, 2020 pursuant to regulation 33 of the listing regulations. A copy of same is enclosed.

Kindly acknowledge the receipt and take the same on your record.

Please note that due to restrictions imposed by complete lockdown to contain the Covid-19 pandemic, SD/- version of the documents is being filed.

Thanking You,

Yours Faithfully,

**For Kabra Drugs Limited**  
**Sd/-**  
**Ramachandran Muralidharan**  
**Director**  
**Din No. 02418630**

---

REGD OFFC: SHOP NO. 270, SHASTRI MARKET, INDORE M.P.  
PHONE NO 0731-4247626  
Email – [kabradrugs@gmail.com](mailto:kabradrugs@gmail.com), [website- www.kabradrugsltd.com](http://www.kabradrugsltd.com)

**KABRA DRUGS LTD.**

CIN:- L02423MP1989PLC005438  
 Regd. Office: Shop No. 270, Shastri Market, Indore - 452001  
 Email:- kabradrugs@rediffmail.com

**(Rs. In lacs)****Statement of Audited Standalone Financial Results for the Year Ended March 31, 2020**

Sl no.	Particulars	Quarter Ended			Year Ended	
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
	<b>(Refer Notes Below)</b>	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>INCOME</b>					
(a)	Revenue From Operation	-	-	-	-	-
(b)	Other Operating Income	2.26	-	-	2.26	0.95
	<b>Total Income from Operations (Net)</b>	<b>2.26</b>	<b>-</b>	<b>-</b>	<b>2.26</b>	<b>0.95</b>
<b>2</b>	<b>EXPENSES</b>					
(a)	Cost of material consumed	-	-	-	-	-
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-
(c)	Employee benefit expense	-	-	-	-	3.41
(d)	Finance Costs	0.12	-	-	0.12	0.58
(e)	Depreciation and amortization expense	3.12	-	-	3.12	3.12
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.11	0.10	0.55	4.98	10.31
	<b>Total Expenses</b>	<b>3.35</b>	<b>0.10</b>	<b>0.55</b>	<b>8.22</b>	<b>17.42</b>
<b>3</b>	<b>Profit / (Loss) from operations before exceptional items Tax (1-2)</b>	<b>(1.09)</b>	<b>(0.10)</b>	<b>(0.55)</b>	<b>(5.96)</b>	<b>(16.47)</b>
4	Exceptional Items	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(1.09)</b>	<b>(0.10)</b>	<b>(0.55)</b>	<b>(5.96)</b>	<b>(16.47)</b>
6	Tax Expense	-	-	-	-	-
<b>7</b>	<b>Net Profit / (Loss) after Tax (5 - 6)</b>	<b>(1.09)</b>	<b>(0.10)</b>	<b>(0.55)</b>	<b>(5.96)</b>	<b>(16.47)</b>
8	Other Comprehensive Income (net of tax )	-	-	-	-	-
<b>9</b>	<b>Total Comprehensive Income for the period (7 ± 8)</b>	<b>(1.09)</b>	<b>(0.10)</b>	<b>(0.55)</b>	<b>(5.96)</b>	<b>(16.47)</b>
10	Paid-up equity share capital (Face Value of Rs.10/- each)	<b>438.86</b>	<b>438.86</b>	<b>438.86</b>	<b>438.86</b>	<b>438.86</b>
11	Other Equity	-	-	-	(441.63)	(435.67)
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- each) (not annualised):</b>					
(a)	Basic	(0.02)	(0.00)	(0.01)	(0.14)	(0.38)
(b)	Diluted	(0.02)	(0.00)	(0.01)	(0.14)	(0.38)

# KABRA DRUGS LTD.

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001

Email:- kabradrugs@rediffmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 31st March, 2020	As at 31st March, 2019
Particulars		Audited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	Property, plant and equipment	4.12	8.05
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	<b>Financial assets</b>		
	Investments	-	-
	Loans	-	-
	Other financial assets	-	3.25
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	2.32	2.38
	<b>Sub-total - Non-Current Assets</b>	<b>6.44</b>	<b>13.68</b>
<b>2</b>	<b>Current assets</b>		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	125.47	125.47
	Cash and cash equivalents	1.02	0.99
	Bank balances other than Cash and Cash equivalents above	0.08	0.09
	Loans, Current	7.13	7.13
	Other financial assets	-	-
	Other current assets	1.34	0.94
	Assets classified as held for sale	-	-
	<b>Sub-total - Current Assets</b>	<b>135.04</b>	<b>134.62</b>
	<b>TOTAL - ASSETS</b>	<b>141.48</b>	<b>148.30</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	Equity Share capital	438.86	438.86
	Other equity	(441.63)	(435.67)
	<b>Sub-total - Shareholders' funds</b>	<b>(2.77)</b>	<b>3.19</b>
<b>2</b>	<b>LIABILITIES</b>		
	<b>Non-current liabilities</b>		
	Financial liabilities		
	Borrowings, non-Current	-	1.60
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	<b>Sub-total - Non-current liabilities</b>	<b>-</b>	<b>1.60</b>
<b>3</b>	<b>Current liabilities</b>		
	Financial liabilities		
	Borrowings, Current	65.25	65.25
	Trade payables, Current	18.73	19.34
	Other financial liabilities	51.92	50.87
	Other current liabilities	8.35	8.05
	Provisions	-	-
	Current tax liabilities (net)	-	-
	<b>Sub-total - Current liabilities</b>	<b>144.25</b>	<b>143.51</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>141.48</b>	<b>148.30</b>

# KABRA DRUGS LTD.

CIN:- L02423MP1989PLC005438  
Regd. Office: Shop No. 270, Shastri Market, Indore - 452001  
Email:- kabradrugs@rediffmail.com

## Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on June 22, 2020.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board  
For, KABRA DRUGS LTD.

SD/-

Place : Indore  
Date : 30th June, 2020

Director/Compliance Officer

**KABRA DRUGS LTD.**  
**CIN:- L02423MP1989PLC005438**  
**Regd. Office: Shop No. 270, Shastri Market, Indore - 452001**  
**STANDALONE STATEMENT OF CASH FLOW**

Particulars	As at 31st March, 2020	As at 31st March, 2019
	(Rs. In lacs)	(Rs. In lacs)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Profit before tax	5.96	16.47
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/ amortization on continuing operation	3.12	3.12
Interest expenses	-	0.37
<b>Operating profit before working capital changes</b>	<b>2.84</b>	<b>13.72</b>
<b>Movement in Working Capital :</b>		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	-	0.51
Increase/(decrease) in Short Term Loan & Advances	-	0.85
Increase/(decrease) in Current Liabilities	1.35	9.15
Increase/(decrease) in Trade Payable	0.61	3.77
Increase/(decrease) in Other Current Assets	0.40	0.04
Direct taxes paid (net of refunds)	-	0.05
<b>Net Cash Flow from Operating Activities(A)</b>	<b>2.50</b>	<b>17.75</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Investments In Shares / withdrawl in Partnership Firm	-	-
Purchase / Sale of Fixed Assets	0.81	-
Interest Received	-	0.95
Change in Bank balances not considered as cash	-	1.19
Increase/(decrease) in Long Term Loan & Advances	-	5.23
<b>Net Cash Flow from Investing Activities(B)</b>	<b>0.81</b>	<b>7.37</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceed (Repayment) from long term borrowing	1.60	0.52
Proceed (Repayment) from short term borrowing	-	-
Finance Cost	-	0.58
Proceed from Other Non Current Assets	3.31	-
<b>Net Cash Flow from Financing Activities(C)</b>	<b>1.71</b>	<b>0.06</b>
Net increase/(decrease) in cash & cash equivalents(A+B+C)	0.02	10.44
Cash and Cash equivalents (Opening Balance)	1.08	11.52
<b>Cash and Cash equivalents (Closing Balance)</b>	<b>1.10</b>	<b>1.08</b>

Previous year figure have been regrouped/ reclassified wherever necessary

The above statement of cash flows has been prepared under the "Indirect Method" as set out in Ind AS - 7, "Statement of Cash Flows"

**Auditor’s Report on Quarterly Financial Results and Year to Date Results of the Company**  
**Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure**  
**Requirements) Regulations, 2015**

To Board of Directors of  
**KABRA DRUGS LTD.**

We have audited the accompanying standalone annual financial results of **KABRA DRUGS LTD.** (hereinafter referred to as the “Company”) for the year ended 31<sup>st</sup> March, 2020 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

**Basis for Opinion**

We conducted our audit in accordance with the standards on auditing (“SAs”) specified under section 143 (10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those SAs are further described in the *Auditor’s Responsibilities for the Audit of the Standalone Financial Results* Section of our report. We are independent of the company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial result under the provision of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

## **Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results**

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and Board of Directors are responsible for the preparation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors ' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matters**

The standalone annual financial results include the results for quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**FOR, RISHI SEKHRI AND ASSOCIATES,  
Chartered Accountants  
FRN: 128216W**

**SD/-  
CA RISHI SEKHRI  
PARTNER  
M.NO. 126656**

**PLACE: MUMBAI  
DATE: 30.06.2020**